{"id":28036,"date":"2026-02-10T14:43:30","date_gmt":"2026-02-10T21:43:30","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=28036"},"modified":"2026-03-20T15:23:25","modified_gmt":"2026-03-20T22:23:25","slug":"ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/","title":{"rendered":"IgIV para la inmunosupresi\u00f3n secundaria asociada a la enfermedad vascular del col\u00e1geno"},"content":{"rendered":"<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7120184\/\">Enfermedad vascular del col\u00e1geno<\/a> Es un grupo de afecciones que causan inflamaci\u00f3n cr\u00f3nica en el col\u00e1geno (un componente clave del tejido conectivo) y las articulaciones circundantes. Dado que no existe cura para estas enfermedades, ciertas terapias inmunosupresoras (p. ej., corticosteroides, metotrexato y <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/cyclophosphamide\/\">ciclofosfamida<\/a>) se utilizan com\u00fanmente para controlar la actividad de la enfermedad vascular del col\u00e1geno.&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-b2e112a9c50786875499103cd0db850b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia financiera\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>Sin embargo, el uso prolongado de estos agentes terap\u00e9uticos con frecuencia resulta en <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2713334\/#sec1\">inmunosupresi\u00f3n significativa<\/a>, tambi\u00e9n conocido como <strong>inmunosupresi\u00f3n secundaria<\/strong>, lo que aumenta la susceptibilidad a infecciones pulmonares y sist\u00e9micas en los pacientes.<\/p>\n\n\n\n<p>En tales casos, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">Terapia con IgIV<\/a> Se utiliza como terapia de refuerzo inmunitario para reducir el riesgo de infecciones oportunistas. Contin\u00fae leyendo para comprender qu\u00e9 son las enfermedades vasculares del col\u00e1geno, c\u00f3mo se desarrolla la inmunosupresi\u00f3n secundaria, la evidencia que respalda el uso de IgIV en este contexto y qu\u00e9 pacientes podr\u00edan beneficiarse m\u00e1s de la terapia con IgIV.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Collagen_Vascular_Diseases_Brief_Overview\" >Enfermedades vasculares del col\u00e1geno: breve descripci\u00f3n general<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Understanding_Secondary_Immunosuppression_in_Collagen-Vascular_Diseases\" >Comprensi\u00f3n de la inmunosupresi\u00f3n secundaria en las enfermedades vasculares del col\u00e1geno<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Treatment-Induced_Hypogammaglobulinemia\" >Hipogammaglobulinemia inducida por el tratamiento<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Clinical_Consequences_of_Secondary_Immunosuppression\" >Consecuencias cl\u00ednicas de la inmunosupresi\u00f3n secundaria<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Clinical_Use_of_IVIG_for_Secondary_Immunosuppression_in_Collagen_Vascular_Diseases\" >Uso cl\u00ednico de la inmunoglobulina intravenosa para la inmunosupresi\u00f3n secundaria en enfermedades vasculares del col\u00e1geno<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#IVIG_in_Hypogammaglobulinemia_and_Reduction_of_Infection_Risk\" >IgIV en la hipogammaglobulinemia y reducci\u00f3n del riesgo de infecci\u00f3n<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Immune_Homeostasis_Without_Further_Suppression\" >Homeostasis inmunitaria sin mayor supresi\u00f3n<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Patient_Selection_and_Clinical_Considerations\" >Selecci\u00f3n de pacientes y consideraciones cl\u00ednicas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#Risks_and_Limitations_of_IVIG\" >Riesgos y limitaciones de la IgIV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#The_Bottom_Line\" >El resultado final<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Collagen_Vascular_Diseases_Brief_Overview\"><\/span><strong>Enfermedades vasculares del col\u00e1geno: breve descripci\u00f3n general<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Las enfermedades vasculares del col\u00e1geno, tambi\u00e9n conocidas como enfermedades del tejido conectivo (ETC), incluyen un grupo de trastornos inmunomediados como el lupus eritematoso sist\u00e9mico (LES), la esclerosis sist\u00e9mica (ES), las miopat\u00edas inflamatorias idiop\u00e1ticas (MII) y la enfermedad mixta del tejido conectivo (EMTC)., <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/an-overview-of-rheumatoid-arthritis\/\">artritis reumatoide<\/a> (AR) y vasculitis.&nbsp;<\/p>\n\n\n\n<p>La mayor\u00eda de estas afecciones se deben a una desregulaci\u00f3n inmunitaria, en la que el sistema inmunitario ataca por error a sus propios tejidos sanos, causando inflamaci\u00f3n. Los s\u00edntomas de las enfermedades vasculares del col\u00e1geno pueden variar entre pacientes, dependiendo del tipo de enfermedad autoinmune que padezcan.&nbsp;<\/p>\n\n\n\n<p>Pero la mayor\u00eda de las formas de enfermedad vascular del col\u00e1geno comparten algunos s\u00edntomas comunes, por ejemplo, fatiga, debilidad muscular, erupci\u00f3n cut\u00e1nea, dolores corporales, fiebre y dolor en las articulaciones.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Understanding_Secondary_Immunosuppression_in_Collagen-Vascular_Diseases\"><\/span><strong>Comprensi\u00f3n de la inmunosupresi\u00f3n secundaria en las enfermedades vasculares del col\u00e1geno<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La inmunosupresi\u00f3n secundaria se refiere a un sistema inmunol\u00f3gico debilitado que ocurre no porque el<strong> <\/strong>El sistema inmunol\u00f3gico est\u00e1 desregulado, pero debido a que est\u00e1 siendo suprimido, generalmente como resultado de<strong> <\/strong>tratamientos utilizados para controlar la propia enfermedad autoinmune.&nbsp;<\/p>\n\n\n\n<p>Muchas personas con enfermedades del col\u00e1geno vascular reciben tratamiento con inmunosupresores potentes (como esteroides, ciclofosfamida o medicamentos biol\u00f3gicos m\u00e1s recientes). Estos tratamientos ayudan a reducir la inflamaci\u00f3n da\u00f1ina, pero tambi\u00e9n debilitan el sistema inmunitario para combatir las infecciones.&nbsp;<\/p>\n\n\n\n<p>Por lo tanto, en las enfermedades vasculares del col\u00e1geno (o ETC), la causa m\u00e1s com\u00fan y cl\u00ednicamente significativa de inmunosupresi\u00f3n secundaria es la exposici\u00f3n prolongada a medicamentos inmunosupresores. Por ejemplo, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2713334\/#sec1\">Los corticosteroides en dosis altas reducen la actividad de los linfocitos y deterioran la funci\u00f3n de las c\u00e9lulas presentadoras de ant\u00edgenos.<\/a>, lo que aumenta el riesgo de crecimiento descontrolado incluso de bacterias, virus, hongos y micobacterias d\u00e9bilmente pat\u00f3genas.<\/p>\n\n\n\n<p>Asimismo, los agentes inmunosupresores convencionales como metotrexato, ciclofosfamida, azatioprina, micofenolato de mofetilo y productos biol\u00f3gicos (p. ej., <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/rituximab-rituxan\/\">rituximab<\/a>) suprimen la proliferaci\u00f3n de linfocitos y <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36562566\/\">producci\u00f3n de anticuerpos, particularmente inmunoglobulina G (IgG),<\/a> lo que compromete a\u00fan m\u00e1s la defensa inmunol\u00f3gica.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Treatment-Induced_Hypogammaglobulinemia\"><\/span><strong>Hipogammaglobulinemia inducida por el tratamiento<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Una manifestaci\u00f3n clave de la inmunosupresi\u00f3n secundaria en las enfermedades vasculares del col\u00e1geno es <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/hypogammaglobulinemia\/\">hipogammaglobulinemia<\/a> (niveles reducidos de IgG) que se produce como resultado de:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36562566\/\">Agotamiento de c\u00e9lulas B<\/a><\/li>\n\n\n\n<li>Deterioro de la supervivencia de las c\u00e9lulas plasm\u00e1ticas<\/li>\n\n\n\n<li>S\u00edntesis de inmunoglobulinas suprimida<\/li>\n<\/ul>\n\n\n\n<p>De hecho, una <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24106215\/\">estudio retrospectivo<\/a> En un estudio de pacientes pedi\u00e1tricos con lupus eritematoso sist\u00e9mico (LES) se encontr\u00f3 que aproximadamente 7% desarrollaron hipogammaglobulinemia (IgG &lt; 500 mg\/dL) durante el seguimiento, lo que indica una inmunosupresi\u00f3n secundaria cl\u00ednicamente relevante.<\/p>\n\n\n\n<p>Aunque las enfermedades col\u00e1geno-vasculares suelen asociarse con la producci\u00f3n de autoanticuerpos, los niveles totales de inmunoglobulina protectora pueden disminuir con el tiempo, especialmente tras un tratamiento inmunosupresor prolongado. Esto crea un estado parad\u00f3jico en el que los pacientes presentan una actividad autoinmune continua junto con una inmunidad humoral efectiva reducida, lo que aumenta el riesgo de infecciones recurrentes.<\/p>\n\n\n\n<div  id=\"call-to-action-dcd0bbd8dece65546666c42c78fff44b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tConsulte a un especialista en IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_Consequences_of_Secondary_Immunosuppression\"><\/span><strong>Consecuencias cl\u00ednicas de la inmunosupresi\u00f3n secundaria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Muchos pacientes con inmunosupresi\u00f3n secundaria asociada a enfermedades vasculares del col\u00e1geno pueden experimentar complicaciones cl\u00ednicas graves, entre ellas:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hipogammaglobulinemia (un sello distintivo de la inmunosupresi\u00f3n secundaria)<\/li>\n\n\n\n<li>Infecciones respiratorias recurrentes<\/li>\n\n\n\n<li>Infecciones oportunistas<\/li>\n\n\n\n<li>Aumento de las tasas de hospitalizaci\u00f3n<\/li>\n\n\n\n<li>Recuperaci\u00f3n tard\u00eda de las infecciones<\/li>\n\n\n\n<li>Limitaciones en el uso de otras terapias inmunosupresoras<\/li>\n<\/ul>\n\n\n\n<p>Estas complicaciones a menudo requieren una modificaci\u00f3n del tratamiento o la adici\u00f3n de terapias de apoyo inmunitario, como la inmunoglobulina intravenosa (IVIG), para restablecer la competencia inmunitaria y permitir al mismo tiempo el control continuo de la enfermedad.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_Use_of_IVIG_for_Secondary_Immunosuppression_in_Collagen_Vascular_Diseases\"><\/span><strong>Uso cl\u00ednico de la inmunoglobulina intravenosa para la inmunosupresi\u00f3n secundaria en enfermedades vasculares del col\u00e1geno<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Varios estudios informaron que la terapia con IgIV puede ayudar a controlar las consecuencias cl\u00ednicas que ocurren como resultado de la inmunosupresi\u00f3n secundaria en pacientes con enfermedades vasculares del col\u00e1geno.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IVIG_in_Hypogammaglobulinemia_and_Reduction_of_Infection_Risk\"><\/span><strong>IgIV en la hipogammaglobulinemia y reducci\u00f3n del riesgo de infecci\u00f3n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Dado que la IgIV proporciona una forma concentrada y purificada de IgG <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/immunoglobulins-ig\/\">anticuerpos<\/a>, Puede ayudar a restablecer los niveles s\u00e9ricos de inmunoglobulina en pacientes con hipogammaglobulinemia secundaria. Esto <strong>inmunidad pasiva<\/strong> Previene infecciones bacterianas, virales y oportunistas, que son una causa importante de morbilidad y mortalidad en pacientes con enfermedad vascular del col\u00e1geno.&nbsp;<\/p>\n\n\n\n<p>Por ejemplo, una <a href=\"https:\/\/doi.org\/10.1177\/0961203313507990\">estudio retrospectivo<\/a> demostraron que la mayor\u00eda de los pacientes pedi\u00e1tricos con lupus eritematoso sist\u00e9mico (LES) con niveles bajos de inmunoglobulina recibieron reemplazo de IgIV para reducir el riesgo de infecci\u00f3n o complicaciones infecciosas activas.&nbsp;<\/p>\n\n\n\n<p>De manera similar, otro <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34054846\/\">estudio de cohorte retrospectivo<\/a> De los pacientes con enfermedades autoinmunes tratados con rituximab, se inform\u00f3 que muchos desarrollaron hipogammaglobulinemia secundaria y el reemplazo de IgIV se inici\u00f3 principalmente debido a infecciones recurrentes o alto riesgo de infecci\u00f3n, en lugar de para el control de la enfermedad autoinmune.&nbsp;<\/p>\n\n\n\n<p>Por lo tanto, este y varios otros estudios sobre enfermedades autoinmunes e inflamatorias demuestran que la IgIV reduce significativamente la frecuencia y la gravedad de las infecciones en pacientes con <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31453435\/\">deficiencia secundaria de anticuerpos, incluidos aquellos que reciben terapias que reducen las c\u00e9lulas B<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Immune_Homeostasis_Without_Further_Suppression\"><\/span><strong>Homeostasis inmunitaria sin mayor supresi\u00f3n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A diferencia de los agentes citot\u00f3xicos, la IgIV no aumenta el riesgo de infecci\u00f3n; en cambio, favorece la recuperaci\u00f3n inmunitaria y permite continuar con la terapia dirigida a la enfermedad cuando sea necesario.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Patient_Selection_and_Clinical_Considerations\"><\/span><strong>Selecci\u00f3n de pacientes y consideraciones cl\u00ednicas<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Aunque la IgIV no es un tratamiento de primera l\u00ednea para las enfermedades vasculares del col\u00e1geno o para la inmunosupresi\u00f3n, se considera espec\u00edficamente en pacientes que cumplen los siguientes criterios:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hipogammaglobulinemia documentada<\/li>\n\n\n\n<li>Infecciones recurrentes o graves<\/li>\n\n\n\n<li>Necesidad continua de terapia inmunosupresora<\/li>\n\n\n\n<li>Contraindicaciones para una mayor supresi\u00f3n inmunitaria<\/li>\n<\/ul>\n\n\n\n<p>En estudios de investigaci\u00f3n, la dosis \u00f3ptima para la inmunosupresi\u00f3n secundaria generalmente sigue <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25310743\/\">reg\u00edmenes de reemplazo<\/a> (p. ej., 400\u2013600 mg\/kg cada 3\u20134 semanas), en lugar de las dosis inmunomoduladoras altas utilizadas para los brotes autoinmunes.<\/p>\n\n\n\n<div  id=\"call-to-action-d416d7ecfc3d0d95cf9724cea93192e0\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risks_and_Limitations_of_IVIG\"><\/span><strong>Riesgos y limitaciones de la IgIV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever.jpg\" alt=\"Patient experiencing fever after IVIG treatment\" class=\"wp-image-28038\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-18x12.jpg 18w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-fever-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>La IgIV generalmente se administra <strong>bien tolerado<\/strong>, pero algunas personas pueden tener <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-common-side-effects-of-ivig-treatment\/\">efectos secundarios<\/a>, incluido:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>dolores de cabeza<\/li>\n\n\n\n<li>Fiebre<\/li>\n\n\n\n<li>Fatiga<\/li>\n\n\n\n<li>N\u00e1useas<\/li>\n\n\n\n<li>Rara vez se presentan problemas m\u00e1s graves, como reacciones al\u00e9rgicas o insuficiencia renal.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Bottom_Line\"><\/span><strong>El resultado final<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los tratamientos est\u00e1ndar para controlar la inflamaci\u00f3n en pacientes tambi\u00e9n plantean un desaf\u00edo \u00fanico: la inmunosupresi\u00f3n secundaria. Si bien la IgIV no cura las enfermedades vasculares del col\u00e1geno, se utiliza como terapia de apoyo para quienes presentan hipogammaglobulinemia documentada y presentan riesgo de infecciones recurrentes o graves.&nbsp;<\/p>\n\n\n\n<p>Si est\u00e1 considerando la terapia con IgIV, debe analizar los posibles beneficios y riesgos con su proveedor de atenci\u00f3n m\u00e9dica para determinar si es la opci\u00f3n adecuada para usted.<\/p>","protected":false},"excerpt":{"rendered":"<p>La enfermedad vascular del col\u00e1geno es un grupo de afecciones que causan inflamaci\u00f3n cr\u00f3nica del col\u00e1geno (un componente clave del tejido conectivo) y las articulaciones circundantes. Dado que no existe cura para estas enfermedades, ciertas terapias inmunosupresoras (p. ej.,<\/p>","protected":false},"author":13,"featured_media":28037,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[17],"class_list":["post-28036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-saba-rassouli"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression<\/title>\n<meta name=\"description\" content=\"Key research on collagen vascular disease, immunosuppression, IVIG use, and hypogammaglobulinemia in lupus and autoimmune disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression\" \/>\n<meta property=\"og:description\" content=\"Key research on collagen vascular disease, immunosuppression, IVIG use, and hypogammaglobulinemia in lupus and autoimmune disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T21:43:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T22:23:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Saba Rassouli, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Saba Rassouli, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/\"},\"author\":{\"name\":\"Dr. Saba Rassouli, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/f70b3467e035aab4ae14bdadd64c5c01\"},\"headline\":\"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression\",\"datePublished\":\"2026-02-10T21:43:30+00:00\",\"dateModified\":\"2026-03-20T22:23:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/\"},\"wordCount\":986,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/ivig-collagen-vascular-disease.jpg\",\"keywords\":[\"Dr. Saba Rassouli\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/\",\"name\":\"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/ivig-collagen-vascular-disease.jpg\",\"datePublished\":\"2026-02-10T21:43:30+00:00\",\"dateModified\":\"2026-03-20T22:23:25+00:00\",\"description\":\"Key research on collagen vascular disease, immunosuppression, IVIG use, and hypogammaglobulinemia in lupus and autoimmune disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/ivig-collagen-vascular-disease.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/ivig-collagen-vascular-disease.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Patient receiving IVIG for Collagen-Vascular Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/ivig\\\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/#\\\/schema\\\/person\\\/f70b3467e035aab4ae14bdadd64c5c01\",\"name\":\"Dr. Saba Rassouli, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"caption\":\"Dr. Saba Rassouli, PharmD\"},\"description\":\"Dr. Saba Rassouli, PharmD was born and raised in Iran. She received her pharmacy degree from Marshall B. Ketchum University in 2022, where she graduated cum laude. The most rewarding part of her job is having the opportunity to care for each patient as if they were family and hearing about how happy and satisfied they are with the services provided by AmeriPharma. In her free time, she likes to go on walks, read books, and try different restaurants and foods.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/saba-rassouli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la inmunosupresi\u00f3n secundaria asociada a la enfermedad vascular del col\u00e1geno","description":"Investigaci\u00f3n clave sobre la enfermedad vascular del col\u00e1geno, la inmunosupresi\u00f3n, el uso de IgIV y la hipogammaglobulinemia en el lupus y los trastornos autoinmunes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression","og_description":"Key research on collagen vascular disease, immunosuppression, IVIG use, and hypogammaglobulinemia in lupus and autoimmune disorders.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2026-02-10T21:43:30+00:00","article_modified_time":"2026-03-20T22:23:25+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg","type":"image\/jpeg"}],"author":"Dr. Saba Rassouli, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Saba Rassouli, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/"},"author":{"name":"Dr. Saba Rassouli, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/f70b3467e035aab4ae14bdadd64c5c01"},"headline":"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression","datePublished":"2026-02-10T21:43:30+00:00","dateModified":"2026-03-20T22:23:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/"},"wordCount":986,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg","keywords":["Dr. Saba Rassouli"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/","url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/","name":"IgIV para la inmunosupresi\u00f3n secundaria asociada a la enfermedad vascular del col\u00e1geno","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg","datePublished":"2026-02-10T21:43:30+00:00","dateModified":"2026-03-20T22:23:25+00:00","description":"Investigaci\u00f3n clave sobre la enfermedad vascular del col\u00e1geno, la inmunosupresi\u00f3n, el uso de IgIV y la hipogammaglobulinemia en el lupus y los trastornos autoinmunes.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg","width":1280,"height":853,"caption":"Patient receiving IVIG for Collagen-Vascular Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-collagen-vascular-disease-associated-secondary-immunosuppression\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Collagen-Vascular Disease-Associated Secondary Immunosuppression"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/es\/#website","url":"https:\/\/ameripharmaspecialty.com\/es\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/es\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/es\/#\/schema\/person\/f70b3467e035aab4ae14bdadd64c5c01","name":"Dra. Saba Rassouli, Farmac\u00e9utica","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","caption":"Dr. Saba Rassouli, PharmD"},"description":"La Dra. Saba Rassouli, doctora en farmacia, naci\u00f3 y creci\u00f3 en Ir\u00e1n. Obtuvo su t\u00edtulo en farmacia en la Universidad Marshall B. Ketchum en 2022, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es tener la oportunidad de atender a cada paciente como si fuera de su familia y escuchar lo contentos y satisfechos que est\u00e1n con los servicios de AmeriPharma. En su tiempo libre, le gusta pasear, leer y probar diferentes restaurantes y comidas.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Saba Rassouli, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"},"uagb_comment_info":0,"uagb_excerpt":"Collagen-vascular disease is a group of conditions that cause chronic inflammation in the collagen (a key component of connective tissue) and surrounding joints. As there is no cure for these diseases, certain immunosuppressive therapies (e.g.,","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2026\/02\/ivig-collagen-vascular-disease.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Saba Rassouli, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Collagen-vascular disease is a group of conditions that cause chronic inflammation in the collagen (a key component of connective tissue) and surrounding joints. As there is no cure for these diseases, certain immunosuppressive therapies (e.g.,","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/28036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=28036"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/28036\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/28037"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=28036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=28036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=28036"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}